NADAC acquisition cost data for AMPHETAMINE SULFATE 10 MG TAB. This is a generic medication, typically more affordable than brand-name equivalents.
| Generic Name | Amphetamine Sulfate |
| Manufacturer | Adare Pharmaceuticals Inc |
| Dosage Form | TABLET, ORALLY DISINTEGRATING |
| Product Type | DRUG FOR FURTHER PROCESSING |
| DEA Schedule | CII |
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00406122001 | $0.8385 | 2022-11-23 | Rx |
| 00527252537 | $0.8385 | 2022-11-23 | Rx |
| 43547045810 | $0.8385 | 2022-11-23 | Rx |
| 43598089801 | $0.8385 | 2022-11-23 | Rx |
| 52536005903 | $0.8385 | 2022-11-23 | Rx |
| 52536005910 | $0.8385 | 2022-11-23 | Rx |
| 57664007588 | $0.8385 | 2022-11-23 | Rx |
| 69238156401 | $0.8385 | 2022-11-23 | Rx |
| 69452022820 | $0.8385 | 2022-11-23 | Rx |
| 70010004101 | $0.8385 | 2022-11-23 | Rx |
Generic: Amphetamine Sulfate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $144.3K | 353 | 142 | $5.07 |
| 2020 | $160.3K | 474 | 138 | $4.17 |
| 2021 | $177.6K | 650 | 146 | $3.35 |
| 2022 | $169.4K | 723 | 177 | $2.97 |
| 2023 | $182.4K | 832 | 203 | $2.80 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $32.6K | 84 | 15 |
| Texas | $15.0K | 101 | 26 |
| New York | $12.6K | 67 | 17 |
| Connecticut | $12.3K | 39 | 11 |
| Michigan | $10.0K | 34 | N/A |
| North Carolina | $9.4K | 69 | 14 |
| Ohio | $9.0K | 23 | N/A |
| Tennessee | $8.9K | 45 | N/A |
| Alabama | $8.5K | 17 | N/A |
| Washington | $8.4K | 37 | N/A |
| Virginia | $7.7K | 31 | N/A |
| New Jersey | $6.6K | 33 | 16 |
| New Hampshire | $4.6K | 12 | N/A |
| Louisiana | $4.4K | 23 | N/A |
| Pennsylvania | $3.5K | 27 | N/A |
| Georgia | $3.4K | 14 | N/A |
| Missouri | $3.3K | 23 | N/A |
| Minnesota | $3.1K | 26 | N/A |
| Illinois | $2.5K | 21 | N/A |
| Kansas | $1.5K | 14 | N/A |
| Kentucky | $1.1K | 13 | N/A |
| Florida | $1.1K | 13 | N/A |
| West Virginia | $542.27 | 12 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.